Access expert perspectives on the evolving precision medicine landscape in this exclusive roundtable report, developed in collaboration with Citeline
Explore the report:
- Why biomarker-driven programs are more likely to advance from Phase I to market approval
- The role of CRO partnerships in supporting highly targeted, early-phase clinical programs
- What biotech leaders really think about regulatory hurdles across regions
- The limits - and promise - of AI and machine learning in drug discovery and trial design
- Why scale, data quality, and standardization are essential to cost control in personalized medicine